• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.

作者信息

Suttorp M J, Polak P E, van 't Hof A, Rasmussen H S, Dunselman P H, Kingma J H

机构信息

Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.

出版信息

Am J Cardiol. 1992 Feb 1;69(4):417-9. doi: 10.1016/0002-9149(92)90247-v.

DOI:10.1016/0002-9149(92)90247-v
PMID:1734660
Abstract
摘要

相似文献

1
Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.新型选择性Ⅲ类抗心律失常药物多非利特对阵发性心房颤动或心房扑动的疗效及安全性
Am J Cardiol. 1992 Feb 1;69(4):417-9. doi: 10.1016/0002-9149(92)90247-v.
2
Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.静脉注射多非利特，一种III类抗心律失常药物，用于终止持续性心房颤动或心房扑动。静脉注射多非利特研究人员。
J Am Coll Cardiol. 1997 Feb;29(2):385-90. doi: 10.1016/s0735-1097(96)00506-2.
3
Dofetilide: a review of its use in atrial fibrillation and atrial flutter.多非利特：其在心房颤动和心房扑动中应用的综述
Drugs. 1999 Dec;58(6):1043-59. doi: 10.2165/00003495-199958060-00007.
4
Dofetilide: is the treatment worse than the disease?多非利特：治疗是否比疾病本身更糟糕？
J Am Coll Cardiol. 2001 Mar 15;37(4):1106-10. doi: 10.1016/s0735-1097(01)01146-9.
5
A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?二十五年后：多非利特的临床作用今如何？
J Cardiovasc Pharmacol Ther. 2019 Jan;24(1):3-10. doi: 10.1177/1074248418784288. Epub 2018 Jun 25.
6
Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.静脉注射多非利特快速终止心房颤动和心房扑动的疗效及安全性。
Am J Cardiol. 2000 Apr 15;85(8):1031-3. doi: 10.1016/s0002-9149(99)00927-3.
7
Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.多非利特治疗先天性心脏病成年患者房性快速性心律失常的临床疗效。
Congenit Heart Dis. 2014 May-Jun;9(3):221-7. doi: 10.1111/chd.12129. Epub 2013 Aug 15.
8
Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.新型III类抗心律失常药物多非利特在冠状动脉搭桥术后急性终止心房颤动或心房扑动中的疗效和安全性。多非利特冠状动脉搭桥术后研究组。
Int J Cardiol. 1997 Jan 31;58(2):135-40. doi: 10.1016/s0167-5273(96)02856-2.
9
Dofetilide: a new drug to control cardiac arrhythmia.
Expert Opin Pharmacother. 2003 Jun;4(6):973-85. doi: 10.1517/14656566.4.6.973.
10
Practical approach to the use and monitoring of dofetilide therapy.
Am J Health Syst Pharm. 2001 Nov 1;58(21):2050-9. doi: 10.1093/ajhp/58.21.2050.

引用本文的文献

1
Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option.心房颤动的当前药物治疗策略以及作为一种新兴的新型治疗选择的TASK-1抑制作用。
Front Pharmacol. 2021 Mar 4;12:638445. doi: 10.3389/fphar.2021.638445. eCollection 2021.
2
Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it.为什么将基础发现转化为房颤的临床应用如此困难，以及改善这种情况的可能方法。
Cardiovasc Res. 2021 Jun 16;117(7):1616-1631. doi: 10.1093/cvr/cvab093.
3
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.
临床无关标准在协变量模型构建中的应用及在多非利特药代动力学数据中的应用
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):503-26. doi: 10.1007/s10928-008-9099-z. Epub 2008 Nov 15.
4
Pharmacological cardioversion of atrial fibrillation: current management and treatment options.心房颤动的药物复律：当前的管理与治疗选择
Drugs. 2004;64(24):2741-62. doi: 10.2165/00003495-200464240-00003.
5
Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia.静脉注射多非利特对房室折返性心动过速诱发的影响。
Heart. 2001 Nov;86(5):522-6. doi: 10.1136/heart.86.5.522.
6
The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing.口服多非利特每日两次和每日三次给药后的药代动力学和药效学。
Br J Clin Pharmacol. 2000 Sep;50(3):247-53. doi: 10.1046/j.1365-2125.2000.00243.x.
7
Effects of intravenous dofetilide in patients with frequent premature ventricular contractions: a clinical trial.静脉注射多非利特对频发室性早搏患者的影响：一项临床试验。
Clin Cardiol. 2000 Jun;23(6):415-6. doi: 10.1002/clc.4960230607.
8
Dofetilide: a review of its use in atrial fibrillation and atrial flutter.多非利特：其在心房颤动和心房扑动中应用的综述
Drugs. 1999 Dec;58(6):1043-59. doi: 10.2165/00003495-199958060-00007.
9
Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide.西咪替丁和雷尼替丁对单剂量多非利特药代动力学和药效学的影响。
Br J Clin Pharmacol. 2000 Jan;49(1):64-71. doi: 10.1046/j.1365-2125.2000.00114.x.
10
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.伊布利特（一种新型III类药物）在转复心房扑动和心房颤动方面优于索他洛尔。伊布利特/索他洛尔对比研究组。
Heart. 1998 Jun;79(6):568-75. doi: 10.1136/hrt.79.6.568.